Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Induction of tryptophan 2,3-dioxygenase expression in human monocytic leukemia/lymphoma cell lines THP-1 and U937.

Hoffmann D, Pilotte L, Stroobant V, Van den Eynde BJ.

Int J Tryptophan Res. 2019 Dec 26;12:1178646919891736. doi: 10.1177/1178646919891736. eCollection 2019.

2.

Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.

Hoffmann D, Dvorakova T, Stroobant V, Bouzin C, Daumerie A, Solvay M, Klaessens S, Letellier MC, Renauld JC, van Baren N, Lelotte J, Marbaix E, Van den Eynde BJ.

Cancer Immunol Res. 2020 Jan;8(1):19-31. doi: 10.1158/2326-6066.CIR-19-0040. Epub 2019 Dec 5.

PMID:
31806639
3.

Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors.

Schramme F, Crosignani S, Frederix K, Hoffmann D, Pilotte L, Stroobant V, Preillon J, Driessens G, Van den Eynde BJ.

Cancer Immunol Res. 2020 Jan;8(1):32-45. doi: 10.1158/2326-6066.CIR-19-0041. Epub 2019 Dec 5.

PMID:
31806638
4.

Two isoprenylated flavonoids from Dorstenia psilurus activate AMPK, stimulate glucose uptake, inhibit glucose production and lower glycemia.

Choumessi AT, Johanns M, Beaufay C, Herent MF, Stroobant V, Vertommen D, Corbet C, Jacobs R, Herinckx G, Steinberg GR, Feron O, Quetin-Leclercq J, Rider MH.

Biochem J. 2019 Dec 19;476(24):3687-3704. doi: 10.1042/BCJ20190326.

PMID:
31782497
5.

Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development.

Balligand T, Achouri Y, Pecquet C, Gaudray G, Colau D, Hug E, Rahmani Y, Stroobant V, Plo I, Vainchenker W, Kralovics R, Van den Eynde BJ, Defour JP, Constantinescu SN.

Leukemia. 2020 Feb;34(2):510-521. doi: 10.1038/s41375-019-0538-1. Epub 2019 Aug 30.

PMID:
31471561
6.

Identifying Antigens Recognized by Cytolytic T Lymphocytes on Tumors.

Vigneron N, Stroobant V, Ma W, Michaux A, Van den Eynde BJ.

Methods Mol Biol. 2019;1988:159-186. doi: 10.1007/978-1-4939-9450-2_13.

PMID:
31147940
7.

The Vacuolar Pathway of Long Peptide Cross-Presentation Can Be TAP Dependent.

Ma W, Stroobant V, Heirman C, Sun Z, Thielemans K, Mulder A, van der Bruggen P, Van den Eynde BJ.

J Immunol. 2019 Jan 15;202(2):451-459. doi: 10.4049/jimmunol.1800353. Epub 2018 Dec 17.

8.

Insight into the Self-Assembling Properties of Peptergents: A Molecular Dynamics Simulation Study.

Crowet JM, Nasir MN, Dony N, Deschamps A, Stroobant V, Morsomme P, Deleu M, Soumillion P, Lins L.

Int J Mol Sci. 2018 Sep 14;19(9). pii: E2772. doi: 10.3390/ijms19092772.

9.

NAT6 acetylates the N-terminus of different forms of actin.

Wiame E, Tahay G, Tyteca D, Vertommen D, Stroobant V, Bommer GT, Van Schaftingen E.

FEBS J. 2018 Sep;285(17):3299-3316. doi: 10.1111/febs.14605. Epub 2018 Aug 13.

10.

Production of spliced peptides by the proteasome.

Vigneron N, Stroobant V, Ferrari V, Abi Habib J, Van den Eynde BJ.

Mol Immunol. 2019 Sep;113:93-102. doi: 10.1016/j.molimm.2018.03.030. Epub 2018 Apr 9. Review.

PMID:
29650230
11.

Peptide splicing by the proteasome.

Vigneron N, Ferrari V, Stroobant V, Abi Habib J, Van den Eynde BJ.

J Biol Chem. 2017 Dec 22;292(51):21170-21179. doi: 10.1074/jbc.R117.807560. Epub 2017 Nov 6. Review.

12.

Constitutive IDO1 Expression in Human Tumors Is Driven by Cyclooxygenase-2 and Mediates Intrinsic Immune Resistance.

Hennequart M, Pilotte L, Cane S, Hoffmann D, Stroobant V, Plaen E, Van den Eynde BJ.

Cancer Immunol Res. 2017 Aug;5(8):695-709. doi: 10.1158/2326-6066.CIR-16-0400. Epub 2017 Jul 21.

13.

Nit1 is a metabolite repair enzyme that hydrolyzes deaminated glutathione.

Peracchi A, Veiga-da-Cunha M, Kuhara T, Ellens KW, Paczia N, Stroobant V, Seliga AK, Marlaire S, Jaisson S, Bommer GT, Sun J, Huebner K, Linster CL, Cooper AJL, Van Schaftingen E.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):E3233-E3242. doi: 10.1073/pnas.1613736114. Epub 2017 Apr 3.

14.

A conserved phosphatase destroys toxic glycolytic side products in mammals and yeast.

Collard F, Baldin F, Gerin I, Bolsée J, Noël G, Graff J, Veiga-da-Cunha M, Stroobant V, Vertommen D, Houddane A, Rider MH, Linster CL, Van Schaftingen E, Bommer GT.

Nat Chem Biol. 2016 Aug;12(8):601-7. doi: 10.1038/nchembio.2104. Epub 2016 Jun 13.

PMID:
27294321
15.

Long-Peptide Cross-Presentation by Human Dendritic Cells Occurs in Vacuoles by Peptide Exchange on Nascent MHC Class I Molecules.

Ma W, Zhang Y, Vigneron N, Stroobant V, Thielemans K, van der Bruggen P, Van den Eynde BJ.

J Immunol. 2016 Feb 15;196(4):1711-20. doi: 10.4049/jimmunol.1501574. Epub 2016 Jan 20.

16.

Novel highly specific anti-periostin antibodies uncover the functional importance of the fascilin 1-1 domain and highlight preferential expression of periostin in aggressive breast cancer.

Field S, Uyttenhove C, Stroobant V, Cheou P, Donckers D, Coutelier JP, Simpson PT, Cummings MC, Saunus JM, Reid LE, Kutasovic JR, McNicol AM, Kim BR, Kim JH, Lakhani SR, Neville AM, Van Snick J, Jat PS.

Int J Cancer. 2016 Apr 15;138(8):1959-70. doi: 10.1002/ijc.29946. Epub 2015 Dec 21.

17.

Polycomb repressive complex 2 and H3K27me3 cooperate with H3K9 methylation to maintain heterochromatin protein 1α at chromatin.

Boros J, Arnoult N, Stroobant V, Collet JF, Decottignies A.

Mol Cell Biol. 2014 Oct 1;34(19):3662-74. doi: 10.1128/MCB.00205-14. Epub 2014 Jul 21.

18.

Metabolite proofreading in carnosine and homocarnosine synthesis: molecular identification of PM20D2 as β-alanyl-lysine dipeptidase.

Veiga-da-Cunha M, Chevalier N, Stroobant V, Vertommen D, Van Schaftingen E.

J Biol Chem. 2014 Jul 11;289(28):19726-36. doi: 10.1074/jbc.M114.576579. Epub 2014 Jun 2.

19.

A short treatment with galactomannan GM-CT-01 corrects the functions of freshly isolated human tumor-infiltrating lymphocytes.

Demotte N, Bigirimana R, Wieërs G, Stroobant V, Squifflet JL, Carrasco J, Thielemans K, Baurain JF, Van Der Smissen P, Courtoy PJ, van der Bruggen P.

Clin Cancer Res. 2014 Apr 1;20(7):1823-33. doi: 10.1158/1078-0432.CCR-13-2459. Epub 2014 Feb 13.

20.

A spliced antigenic peptide comprising a single spliced amino acid is produced in the proteasome by reverse splicing of a longer peptide fragment followed by trimming.

Michaux A, Larrieu P, Stroobant V, Fonteneau JF, Jotereau F, Van den Eynde BJ, Moreau-Aubry A, Vigneron N.

J Immunol. 2014 Feb 15;192(4):1962-71. doi: 10.4049/jimmunol.1302032. Epub 2014 Jan 22.

21.

Database of T cell-defined human tumor antigens: the 2013 update.

Vigneron N, Stroobant V, Van den Eynde BJ, van der Bruggen P.

Cancer Immun. 2013 Jul 15;13:15. Print 2013. Review.

22.

Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A.

Dolušić E, Larrieu P, Meinguet C, Colette D, Rives A, Blanc S, Ferain T, Pilotte L, Stroobant V, Wouters J, Van den Eynde B, Masereel B, Delfourne E, Frédérick R.

Bioorg Med Chem Lett. 2013 Jan 1;23(1):47-54. doi: 10.1016/j.bmcl.2012.11.036. Epub 2012 Nov 22.

PMID:
23218716
23.

Analysis of the processing of seven human tumor antigens by intermediate proteasomes.

Guillaume B, Stroobant V, Bousquet-Dubouch MP, Colau D, Chapiro J, Parmentier N, Dalet A, Van den Eynde BJ.

J Immunol. 2012 Oct 1;189(7):3538-47. Epub 2012 Aug 27.

24.

Inefficient exogenous loading of a tapasin-dependent peptide onto HLA-B*44:02 can be improved by acid treatment or fixation of target cells.

Stroobant V, Demotte N, Luiten RM, Leonhardt RM, Cresswell P, Bonehill A, Michaux A, Ma W, Mulder A, Van den Eynde BJ, van der Bruggen P, Vigneron N.

Eur J Immunol. 2012 Jun;42(6):1417-28. doi: 10.1002/eji.201141954.

25.

Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition.

Röhrig UF, Majjigapu SR, Grosdidier A, Bron S, Stroobant V, Pilotte L, Colau D, Vogel P, Van den Eynde BJ, Zoete V, Michielin O.

J Med Chem. 2012 Jun 14;55(11):5270-90. doi: 10.1021/jm300260v. Epub 2012 May 22.

PMID:
22616902
26.

Loss of effector function of human cytolytic T lymphocytes is accompanied by major alterations in N- and O-glycosylation.

Antonopoulos A, Demotte N, Stroobant V, Haslam SM, van der Bruggen P, Dell A.

J Biol Chem. 2012 Mar 30;287(14):11240-51. doi: 10.1074/jbc.M111.320820. Epub 2012 Feb 13.

27.

Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.

Pilotte L, Larrieu P, Stroobant V, Colau D, Dolusic E, Frédérick R, De Plaen E, Uyttenhove C, Wouters J, Masereel B, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2497-502. doi: 10.1073/pnas.1113873109. Epub 2012 Jan 30.

28.

Molecular identification of hydroxylysine kinase and of ammoniophospholyases acting on 5-phosphohydroxy-L-lysine and phosphoethanolamine.

Veiga-da-Cunha M, Hadi F, Balligand T, Stroobant V, Van Schaftingen E.

J Biol Chem. 2012 Mar 2;287(10):7246-55. doi: 10.1074/jbc.M111.323485. Epub 2012 Jan 12.

29.

Ethylmalonyl-CoA decarboxylase, a new enzyme involved in metabolite proofreading.

Linster CL, Noël G, Stroobant V, Vertommen D, Vincent MF, Bommer GT, Veiga-da-Cunha M, Van Schaftingen E.

J Biol Chem. 2011 Dec 16;286(50):42992-3003. doi: 10.1074/jbc.M111.281527. Epub 2011 Oct 20.

30.

Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.

Dolusić E, Larrieu P, Moineaux L, Stroobant V, Pilotte L, Colau D, Pochet L, Van den Eynde B, Masereel B, Wouters J, Frédérick R.

J Med Chem. 2011 Aug 11;54(15):5320-34. doi: 10.1021/jm2006782. Epub 2011 Jul 18.

PMID:
21726069
31.

An antigenic peptide produced by reverse splicing and double asparagine deamidation.

Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):E323-31. doi: 10.1073/pnas.1101892108. Epub 2011 Jun 13.

32.

Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

Dolušić E, Larrieu P, Blanc S, Sapunaric F, Pouyez J, Moineaux L, Colette D, Stroobant V, Pilotte L, Colau D, Ferain T, Fraser G, Galleni M, Frère JM, Masereel B, Van den Eynde B, Wouters J, Frédérick R.

Eur J Med Chem. 2011 Jul;46(7):3058-65. doi: 10.1016/j.ejmech.2011.02.049. Epub 2011 Feb 26.

33.

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.

Dolušić E, Larrieu P, Blanc S, Sapunaric F, Norberg B, Moineaux L, Colette D, Stroobant V, Pilotte L, Colau D, Ferain T, Fraser G, Galleni M, Frère JM, Masereel B, Van den Eynde B, Wouters J, Frédérick R.

Bioorg Med Chem. 2011 Feb 15;19(4):1550-61. doi: 10.1016/j.bmc.2010.12.032. Epub 2010 Dec 16. Erratum in: Bioorg Med Chem. 2011 May 1;19(9):3029. Galeni, Moreno [corrected to Galleni, Moreno].

34.

Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases.

Corbière V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethé B, van Baren N, Van den Eynde BJ, Boon T, Coulie PG.

Cancer Res. 2011 Feb 15;71(4):1253-62. doi: 10.1158/0008-5472.CAN-10-2693. Epub 2011 Jan 7.

35.

A MAGE-C2 antigenic peptide processed by the immunoproteasome is recognized by cytolytic T cells isolated from a melanoma patient after successful immunotherapy.

Ma W, Vigneron N, Chapiro J, Stroobant V, Germeau C, Boon T, Coulie PG, Van den Eynde BJ.

Int J Cancer. 2011 Nov 15;129(10):2427-34. doi: 10.1002/ijc.25911. Epub 2011 Apr 20.

36.

Differences in the production of spliced antigenic peptides by the standard proteasome and the immunoproteasome.

Dalet A, Stroobant V, Vigneron N, Van den Eynde BJ.

Eur J Immunol. 2011 Jan;41(1):39-46. doi: 10.1002/eji.201040750. Epub 2010 Dec 9.

37.

Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules.

Guillaume B, Chapiro J, Stroobant V, Colau D, Van Holle B, Parvizi G, Bousquet-Dubouch MP, Théate I, Parmentier N, Van den Eynde BJ.

Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18599-604. doi: 10.1073/pnas.1009778107. Epub 2010 Oct 11.

38.

Molecular identification of N-acetylaspartylglutamate synthase and beta-citrylglutamate synthase.

Collard F, Stroobant V, Lamosa P, Kapanda CN, Lambert DM, Muccioli GG, Poupaert JH, Opperdoes F, Van Schaftingen E.

J Biol Chem. 2010 Sep 24;285(39):29826-33. doi: 10.1074/jbc.M110.152629. Epub 2010 Jul 24.

39.

Molecular identification of NAT8 as the enzyme that acetylates cysteine S-conjugates to mercapturic acids.

Veiga-da-Cunha M, Tyteca D, Stroobant V, Courtoy PJ, Opperdoes FR, Van Schaftingen E.

J Biol Chem. 2010 Jun 11;285(24):18888-98. doi: 10.1074/jbc.M110.110924. Epub 2010 Apr 13.

40.

Production of an antigenic peptide by insulin-degrading enzyme.

Parmentier N, Stroobant V, Colau D, de Diesbach P, Morel S, Chapiro J, van Endert P, Van den Eynde BJ.

Nat Immunol. 2010 May;11(5):449-54. doi: 10.1038/ni.1862. Epub 2010 Apr 4.

PMID:
20364150
41.

Splicing of distant peptide fragments occurs in the proteasome by transpeptidation and produces the spliced antigenic peptide derived from fibroblast growth factor-5.

Dalet A, Vigneron N, Stroobant V, Hanada K, Van den Eynde BJ.

J Immunol. 2010 Mar 15;184(6):3016-24. doi: 10.4049/jimmunol.0901277. Epub 2010 Feb 12.

42.

Molecular identification of carnosine synthase as ATP-grasp domain-containing protein 1 (ATPGD1).

Drozak J, Veiga-da-Cunha M, Vertommen D, Stroobant V, Van Schaftingen E.

J Biol Chem. 2010 Mar 26;285(13):9346-56. doi: 10.1074/jbc.M109.095505. Epub 2010 Jan 22.

43.

Rational design of indoleamine 2,3-dioxygenase inhibitors.

Röhrig UF, Awad L, Grosdidier A, Larrieu P, Stroobant V, Colau D, Cerundolo V, Simpson AJ, Vogel P, Van den Eynde BJ, Zoete V, Michielin O.

J Med Chem. 2010 Feb 11;53(3):1172-89. doi: 10.1021/jm9014718.

PMID:
20055453
44.

Determination of the minimal fusion peptide of HIV, SIV and BLV fusion glycoproteins.

Lorin A, Charloteaux B, Lins L, Stroobant V, Brasseur R.

Adv Exp Med Biol. 2009;611:387-8. No abstract available.

PMID:
19400236
45.

Biochemical characterization of dithiol glutaredoxin 8 from Saccharomyces cerevisiae: the catalytic redox mechanism redux.

Eckers E, Bien M, Stroobant V, Herrmann JM, Deponte M.

Biochemistry. 2009 Feb 17;48(6):1410-23. doi: 10.1021/bi801859b.

PMID:
19166312
46.

Characterization of mammalian sedoheptulokinase and mechanism of formation of erythritol in sedoheptulokinase deficiency.

Kardon T, Stroobant V, Veiga-da-Cunha M, Schaftingen EV.

FEBS Lett. 2008 Oct 15;582(23-24):3330-4. doi: 10.1016/j.febslet.2008.08.024. Epub 2008 Sep 5.

47.

Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway.

El Hage F, Stroobant V, Vergnon I, Baurain JF, Echchakir H, Lazar V, Chouaib S, Coulie PG, Mami-Chouaib F.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10119-24. doi: 10.1073/pnas.0802753105. Epub 2008 Jul 14.

48.

Molecular identification of pseudouridine-metabolizing enzymes.

Preumont A, Snoussi K, Stroobant V, Collet JF, Van Schaftingen E.

J Biol Chem. 2008 Sep 12;283(37):25238-46. doi: 10.1074/jbc.M804122200. Epub 2008 Jun 30.

49.

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.

Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P.

Immunity. 2008 Mar;28(3):414-24. doi: 10.1016/j.immuni.2008.01.011.

50.

The minimal fusion peptide of simian immunodeficiency virus corresponds to the 11 first residues of gp32.

Lorin A, Lins L, Stroobant V, Brasseur R, Charloteaux B.

J Pept Sci. 2008 Apr;14(4):423-8.

PMID:
17994611

Supplemental Content

Loading ...
Support Center